Article
Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.
The Journal of antimicrobial chemotherapy - 4 Aug 2026
Bellecave Pantxika, Peyrouny-Mazeau Alaric, Leleux Olivier, Hessamfar Mojgan, Le Moal Gwenaël, Neau Didier, Alleman Laure, Cazanave Charles, Lazaro Estibaliz, Duffau Pierre, Vandenhende Marie-Anne, Castan Bernard, Tumiotto Camille, Bonnet Fabrice
Abstract excerpt
OBJECTIVES: We investigated, in a real-world setting, virological factors associated with virological failure (VF) after bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) initiation in people with HIV (PWH) with and without pre-existing drug resistance mutation (PRM) and the emergence of new resistance mutations at virological failure. METHODS: Treatment-experienced PWH from ANRS-CO3-AquiVIH-NA cohort...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.